Combining chemotherapy, targeted therapy, and immunotherapy to shrink advanced liver cancer

Plain-English translation of NCT07483359 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a combination of three cancer treatments — chemotherapy delivered directly to the liver, a daily pill called Lenvatinib, and an immunotherapy injection — to shrink advanced liver cancer tumors, especially those with blood clots in the portal vein. The goal is to make these tumors small enough and manageable enough that doctors can surgically remove them completely. This approach is called 'conversion therapy' because it aims to convert tumors that cannot be operated on into ones that can be.

Some people with advanced liver cancer have tumors too large or in locations that make surgery too risky or impossible. This treatment combines three different approaches to attack the cancer from multiple angles, hoping to shrink tumors enough that surgery becomes a real option and can completely remove the cancer.

Do you qualify?

You likely qualify if…

you are between 18 and 80 years old
you have been diagnosed with hepatocellular carcinoma (liver cancer) that cannot currently be surgically removed
you have a blood clot in your portal vein (a major blood vessel in the liver) confirmed by imaging
you have adequate liver, kidney, and bone marrow function based on blood tests
you have not received any prior systemic cancer treatments such as chemotherapy, targeted therapy, or immunotherapy
you are in good enough overall health to tolerate the treatment (ECOG performance status of 0 or 1)

You likely don't qualify if…

you have cancer that has spread outside the liver to other parts of your body
you have had another type of cancer in the past 5 years (with limited exceptions)
you are pregnant, breastfeeding, or unwilling to use birth control during and after treatment
you have severe liver disease (Child-Pugh class C) or severely impaired organ function
you have active bleeding problems or a history of certain blood clots

What participation looks like

You would receive treatment in 21-day cycles, with chemotherapy delivered through a catheter directly into the liver blood vessels, a daily oral targeted therapy pill, and periodic immunotherapy infusions. Every two cycles (about 6 weeks), you would have imaging scans to see how well the treatment is working, and doctors would decide if your tumor has shrunk enough for surgery. If surgery becomes possible, you would have the operation. If not, treatment would continue for up to 6 months of chemotherapy and up to 2 years of the other medications, with regular follow-up scans and blood tests throughout.

AI-generated summary from trial data · Jun 7, 2026 · Not medical advice

Trial locations(1 site)

China

The First Hospital of China Medical University, Shenyang, Liaoning